These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 23807371)

  • 1. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial.
    Bressler SB; Qin H; Melia M; Bressler NM; Beck RW; Chan CK; Grover S; Miller DG;
    JAMA Ophthalmol; 2013 Aug; 131(8):1033-40. PubMed ID: 23807371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation.
    ; Googe J; Brucker AJ; Bressler NM; Qin H; Aiello LP; Antoszyk A; Beck RW; Bressler SB; Ferris FL; Glassman AR; Marcus D; Stockdale CR
    Retina; 2011 Jun; 31(6):1009-27. PubMed ID: 21394052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.
    ; Elman MJ; Aiello LP; Beck RW; Bressler NM; Bressler SB; Edwards AR; Ferris FL; Friedman SM; Glassman AR; Miller KM; Scott IU; Stockdale CR; Sun JK
    Ophthalmology; 2010 Jun; 117(6):1064-1077.e35. PubMed ID: 20427088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema.
    Bressler SB; Glassman AR; Almukhtar T; Bressler NM; Ferris FL; Googe JM; Gupta SK; Jampol LM; Melia M; Wells JA;
    Am J Ophthalmol; 2016 Apr; 164():57-68. PubMed ID: 26802783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.
    Elman MJ; Bressler NM; Qin H; Beck RW; Ferris FL; Friedman SM; Glassman AR; Scott IU; Stockdale CR; Sun JK;
    Ophthalmology; 2011 Apr; 118(4):609-14. PubMed ID: 21459214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation.
    Bressler NM; Edwards AR; Beck RW; Flaxel CJ; Glassman AR; Ip MS; Kollman C; Kuppermann BD; Stone TW;
    Arch Ophthalmol; 2009 Dec; 127(12):1566-71. PubMed ID: 20008708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results.
    ; Elman MJ; Qin H; Aiello LP; Beck RW; Bressler NM; Ferris FL; Glassman AR; Maturi RK; Melia M
    Ophthalmology; 2012 Nov; 119(11):2312-8. PubMed ID: 22999634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.
    Dewan V; Lambert D; Edler J; Kymes S; Apte RS
    Ophthalmology; 2012 Aug; 119(8):1679-84. PubMed ID: 22503301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy.
    Diabetic Retinopathy Clinical Research Network*
    JAMA Ophthalmol; 2013 Mar; 131(3):283-93. PubMed ID: 23370902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical Lessons from Protocol I for the Management of Diabetic Macular Edema.
    Mukkamala L; Bhagat N; Zarbin MA
    Dev Ophthalmol; 2017; 60():91-108. PubMed ID: 28427069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.
    Ip MS; Domalpally A; Sun JK; Ehrlich JS
    Ophthalmology; 2015 Feb; 122(2):367-74. PubMed ID: 25439595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results.
    Elman MJ; Ayala A; Bressler NM; Browning D; Flaxel CJ; Glassman AR; Jampol LM; Stone TW;
    Ophthalmology; 2015 Feb; 122(2):375-81. PubMed ID: 25439614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab.
    Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Jampol LM; Melia M; Peters MA; Rauser ME;
    Ophthalmology; 2017 Apr; 124(4):431-439. PubMed ID: 28161147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of masking study participants to intravitreal injections in a randomized clinical trial.
    Glassman AR; Stockdale CR; Beck RW; Baker C; Bressler NM;
    Arch Ophthalmol; 2012 Feb; 130(2):190-4. PubMed ID: 22332211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema.
    Soheilian M; Garfami KH; Ramezani A; Yaseri M; Peyman GA
    Retina; 2012 Feb; 32(2):314-21. PubMed ID: 22234244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Panretinal photocoagulation and intravitreal triamcinolone acetonide for the management of proliferative diabetic retinopathy with macular edema.
    Zein WM; Noureddin BN; Jurdi FA; Schakal A; Bashshur ZF
    Retina; 2006 Feb; 26(2):137-42. PubMed ID: 16467667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of ranibizumab on diabetic retinopathy severity and progression.
    Ip MS; Domalpally A; Hopkins JJ; Wong P; Ehrlich JS
    Arch Ophthalmol; 2012 Sep; 130(9):1145-52. PubMed ID: 22965590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab.
    Bressler SB; Qin H; Beck RW; Chalam KV; Kim JE; Melia M; Wells JA;
    Arch Ophthalmol; 2012 Sep; 130(9):1153-61. PubMed ID: 22965591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
    Gross JG; Glassman AR; Liu D; Sun JK; Antoszyk AN; Baker CW; Bressler NM; Elman MJ; Ferris FL; Gardner TW; Jampol LM; Martin DF; Melia M; Stockdale CR; Beck RW;
    JAMA Ophthalmol; 2018 Oct; 136(10):1138-1148. PubMed ID: 30043039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema.
    Diabetic Retinopathy Clinical Research Network
    Ophthalmology; 2008 Sep; 115(9):1447-9, 1449.e1-10. PubMed ID: 18662829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.